Radotinib
![]() |
- ₹0
- Product name: Radotinib
- CAS: 926037-48-1
- MF: C27H21F3N8O
- MW: 530.5
- EINECS:
- MDL Number:MFCD27956910
- Synonyms:IY5511;Radotinib;Radotinib(IY-5511);4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-(4-(pyrazin-2-yl)pyrimidin-2-ylamino)benzamide;4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phe...;Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(2-pyrazinyl)-2-pyrimidinyl]amino]-;RADOTINIB; IY5511 HCL.;IY5511 HCl.
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|
Properties
Density :1.40±0.1 g/cm3(Predicted)
storage temp. :Store at -20°C
solubility :≥26.55 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
form :solid
pka :12.94±0.70(Predicted)
color :Light yellow to yellow
storage temp. :Store at -20°C
solubility :≥26.55 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
form :solid
pka :12.94±0.70(Predicted)
color :Light yellow to yellow
Safety Information
Symbol(GHS): |
![]() ![]() ![]() |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Danger | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Precautionary statements: |
|
Description
Radotinib, an inhibitor of Bcr–Abl tyrosine kinase,was approved in January 2012 in Korea as a second-line treatment for chronic myeloid leukemia (CML). Radotinib is a TKI with a similar structure to the second-generation TKI, nilotinib, in which a pyridyl group has been replaced with a pyrazinemoiety. The in vitro activity of radotinib against a variety of tumor cell lines is disclosed in an issued patent. Radotinib was significantly more potent than imatinib in all of the cell lines tested. The synthesis of radotinib via amide coupling is described in the patent literature.Related product price
- FASUDIL
₹14260 - Rapamycin
₹4194-370089 - Temsirolimus
₹14115.8-51732.68